ALK-Abello A/S
CSE:ALK B

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
CSE:ALK B
Watchlist
Price: 158.1 DKK -1.98%
Market Cap: 35B DKK
Have any thoughts about
ALK-Abello A/S?
Write Note

ALK-Abello A/S
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ALK-Abello A/S
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
ALK-Abello A/S
CSE:ALK B
Short-Term Debt
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Novo Nordisk A/S
CSE:NOVO B
Short-Term Debt
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H Lundbeck A/S
CSE:HLUN A
Short-Term Debt
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Stenocare A/S
CSE:STENO
Short-Term Debt
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ALK-Abello A/S
Glance View

Market Cap
35B DKK
Industry
Pharmaceuticals

ALK-Abelló A/S is a fascinating player in the global pharmaceutical market, renowned for its dedication to alleviating the impact of allergies through innovative treatments. Born in the heart of Denmark, this company has carved a niche for itself by focusing intensely on developing immunotherapy solutions for allergy sufferers—a sector often overshadowed by more glamorous pharmaceutical pursuits. ALK-Abelló operates at the forefront of the allergen immunotherapy landscape, committed to transforming the lives of those affected by allergic conditions, such as hay fever and allergic asthma. The company's portfolio includes allergy immunotherapy tablets, injection-based treatments, and diagnostic devices designed to offer comprehensive allergy solutions, catering to both established and emerging markets. The essence of ALK-Abelló’s business model lies in its strategic focus on the research, development, and commercialization of allergy immunotherapies. Through rigorous scientific research and development, the company has developed a series of groundbreaking allergy tablets that provide patients with a convenient, effective alternative to traditional injection-based treatments. This innovation not only harnesses scientific advancements but also addresses consumer demand for ease and efficacy. Revenue streams are predominantly generated through the sale of these innovative products to healthcare providers and patients, a process supported by strong partnerships with clinical professionals and an extensive distribution network. In essence, ALK-Abelló finds its competitive edge in delivering tailored, cutting-edge allergy treatments that not only improve patient outcomes but also promise to reduce the long-term economic burden of allergic diseases.

ALK B Intrinsic Value
153.16 DKK
Overvaluation 3%
Intrinsic Value
Price

See Also

What is ALK-Abello A/S's Short-Term Debt?
Short-Term Debt
0 DKK

Based on the financial report for Dec 31, 2023, ALK-Abello A/S's Short-Term Debt amounts to 0 DKK.

Back to Top